{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:11:20Z","timestamp":1790964680835,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1093\/neuonc\/nox020","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T08:58:08Z","timestamp":1487149088000},"page":"845-852","source":"Crossref","is-referenced-by-count":53,"title":["Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas"],"prefix":"10.1093","volume":"19","author":[{"given":"Matthias","family":"Holdhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey G.","family":"Supko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis B.","family":"Nabors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Walbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"key\n\t\t\t\t20170608122038_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2008\u20132012","volume":"17","year":"2015","journal-title":"Neuro Oncol"},{"issue":"1","key":"key\n\t\t\t\t20170608122038_CIT0002","first-page":"307","article-title":"Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial","volume":"9","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"key\n\t\t\t\t20170608122038_CIT0003","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood.V74.5.1499.1499","article-title":"A two-step timed sequential treatment for acute myelocytic leukemia","volume":"74","year":"1989","journal-title":"Blood"},{"issue":"7 Pt 1","key":"key\n\t\t\t\t20170608122038_CIT0004","first-page":"2138","article-title":"Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors","volume":"37","year":"1977","journal-title":"Cancer Res"},{"issue":"2","key":"key\n\t\t\t\t20170608122038_CIT0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-012-0995-0","article-title":"Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model","volume":"111","year":"2013","journal-title":"J Neurooncol"},{"issue":"3","key":"key\n\t\t\t\t20170608122038_CIT0006","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-15-0456","article-title":"T-type Ca2+ channel inhibition sensitizes ovarian cancer to carboplatin","volume":"15","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"key\n\t\t\t\t20170608122038_CIT0007","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00424-014-1444-z","article-title":"T-type calcium channels blockers as new tools in cancer therapies","volume":"466","year":"2014","journal-title":"Pflugers Arch"},{"issue":"7","key":"key\n\t\t\t\t20170608122038_CIT0008","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bcp.2012.12.017","article-title":"Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells","volume":"85","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t20170608122038_CIT0009","first-page":"v18","article-title":"Inhibition of T-type calcium channels sensitizes glioblastoma stem cells to chemotherapy [abstract]","volume":"17","year":"2015","journal-title":"Neuro Oncol"},{"issue":"6","key":"key\n\t\t\t\t20170608122038_CIT0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ceca.2004.05.001","article-title":"The role of voltage gated T-type Ca2+ channel isoforms in mediating \u201ccapacitative\u201d Ca2+ entry in cancer cells","volume":"36","year":"2004","journal-title":"Cell Calcium"},{"issue":"2","key":"key\n\t\t\t\t20170608122038_CIT0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ceca.2006.04.017","article-title":"T-type calcium channels in differentiation and proliferation","volume":"40","year":"2006","journal-title":"Cell Calcium"},{"issue":"4","key":"key\n\t\t\t\t20170608122038_CIT0012","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1476-5381.2012.01852.x","article-title":"Inhibition of T-type Ca\u00b2\u207a channels by endostatin attenuates human glioblastoma cell proliferation and migration","volume":"166","year":"2012","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20170608122038_CIT0013","first-page":"v13","article-title":"Mibefradil dihydrochloride with hypofractionated radiation for recurrent glioblastoma: preliminary results of a phase I dose expansion trial [abstract]","volume":"17","year":"2015","journal-title":"Neuro Oncol"},{"issue":"4B","key":"key\n\t\t\t\t20170608122038_CIT0014","first-page":"40C","article-title":"Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist","volume":"80","year":"1997","journal-title":"Am J Cardiol"},{"issue":"9119","key":"key\n\t\t\t\t20170608122038_CIT0015","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(05)78800-0","article-title":"What lessons can be learnt from withdrawal of mibefradil from the market?","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"key\n\t\t\t\t20170608122038_CIT0016","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170608122038_CIT0017","volume-title":"Pharmacokinetic\/Pharmacodynamic Data Analysis: Concepts and Applications","year":"1994"},{"issue":"1","key":"key\n\t\t\t\t20170608122038_CIT0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10543409708835177","article-title":"Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?","volume":"7","year":"1997","journal-title":"J Biopharm Stat"},{"issue":"4","key":"key\n\t\t\t\t20170608122038_CIT0019","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1248\/cpb.33.1620","article-title":"Preparation of mean drug concentration\u2013time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters","volume":"33","year":"1985","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"282","key":"key\n\t\t\t\t20170608122038_CIT0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","year":"1958","journal-title":"J Amer Statist Assn"},{"issue":"1","key":"key\n\t\t\t\t20170608122038_CIT0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","year":"1982","journal-title":"Biometrics"},{"key":"key\n\t\t\t\t20170608122038_CIT0022","article-title":"Repeatability of 18F-FLT PET in a multi-center study of patients with high grade glioma","year":"2016","journal-title":"J Nucl Med"},{"issue":"6","key":"key\n\t\t\t\t20170608122038_CIT0023","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003088-199835060-00001","article-title":"Clinical pharmacokinetics of mibefradil","volume":"35","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"key\n\t\t\t\t20170608122038_CIT0024","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.2042-7158.1998.tb06912.x","article-title":"Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects","volume":"50","year":"1998","journal-title":"J Pharm Pharmacol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/19\/6\/845\/17687262\/nox020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T12:15:09Z","timestamp":1601640909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/nox020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,3,22]]},"published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nox020","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}